View the public protocol
GlaxoSmithKline Biologicals SA, Harvard Pilgrim Health Care Institute,CVS Health, Carelon Research, HealthPartners, Humana, Point32Health. A post-marketing active surveillance study to evaluate the risk of Guillain-Barré syndrome, acute disseminated encephalomyelitis, and atrial fibrillation in adults 50 years and older vaccinated with GSK’s Arexvy vaccine in the United States (220149) (EUPAS1000000486). Amsterdam: European Medicines Agency (EMA); 2025 Mar 6. Available from: https://catalogues.ema.europa.eu/node/4387/administrative-details
